Axsome Therapeutics(US:AXSM) Financial Modeling Prep·2026-02-23 18:02Core Insights - Axsome Therapeutics reported an earnings per share (EPS) of -$0.56 for February 23, 2026, which was better than the expected -$0.70, indicating better-than-anticipated performance [1] - The company achieved a revenue of approximately $196 million, surpassing the estimated $193.3 million, suggesting successful sales growth [2] Financial Metrics - The price-to-sales ratio stands at 16.50, reflecting investor confidence in the company's future growth potential [2] - Axsome has a negative P/E ratio of -40.04 and an earnings yield of -2.50%, indicating a lack of profitability [3] - The current ratio of 1.57 suggests a reasonable level of short-term liquidity to cover current liabilities [3] Valuation and Debt - The enterprise value to sales ratio is 16.31, indicating that the company's valuation is closely tied to its revenue [4] - The enterprise value to operating cash flow ratio is significantly negative at -90.69, highlighting challenges in generating positive cash flow from operations [4] - The debt-to-equity ratio of 2.96 indicates a higher level of debt compared to equity, which could pose risks if the company cannot generate sufficient cash flow to service its debt [4]